Evidence map›Paper›PMID 34367726›Full record

ArticleClinical & experimental pharmacology2021

Predicting the Severity of Disease Progression in COVID-19 at the Individual and Population Level: A Mathematical Model.

Narendra Chirmule, Ravindra Khare, Pradip Nair, Bela Desai, Vivek Nerurkar, Amitabh Gaur

Open access · goldAbstract read
In one paragraph

Article in Clinical & experimental pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Narendra ChirmuleSymphony Tech Biologics, Pennsylvania, USA.
Ravindra KhareSymphony Tech Biologics, Pennsylvania, USA.
Pradip NairBiocon Research Limited, Karnataka, India.
Bela DesaiNano Cellect Biomedical, California, USA.
Vivek NerurkarDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii, Hawaii, USA.
Amitabh GaurInnovative Assay Solutions LLC, California, USA.
Biocon (India) · INNanoCellect Biomedical (United States) · USUniversity of Hawaiʻi at Mānoa · US

Funding

Small Grants ProgramP30GM114737 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI NERURKAR, VIVEK RAMCHANDRA · 2015 to 2022
$8.1M
NIGMS NIH HHS P30 GM114737
6 · The paper itself

Abstract

The impact of COVID-19 disease on health and economy has been global, and the magnitude of devastation is unparalleled in modern history. Any potential course of action to manage this complex disease requires the systematic and efficient analysis of data that can delineate the underlying pathogenesis. We have developed a mathematical model of disease progression to predict the clinical outcome, utilizing a set of causal factors known to contribute to COVID-19 pathology such as age, comorbidities, and certain viral and immunological parameters. Viral load and selected indicators of a dysfunctional immune response, such as cytokines IL-6 and IFNα which contribute to the cytokine storm and fever, parameters of inflammation D-Dimer and Ferritin, aberrations in lymphocyte number, lymphopenia, and neutralizing antibodies were included for the analysis. The model provides a framework to unravel the multi-factorial complexities of the immune response manifested in SARS-CoV-2 infected individuals. Further, this model can be valuable to predict clinical outcome at an individual level, and to develop strategies for allocating appropriate resources to manage severe cases at a population level.

Indexed as

Cytokine-stormInnateInterferonLymphopeniaModelingNeutralizing-antibodiesPredictionViral factors

Identifiers

PMID34367726
PMCPMC8343949
OpenAlexW3168927507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.